Charles River Labs (CRL) Stock Research

Friday

Charles River price target raised by $40 at Morgan Stanley

Aug 7, 9:29 AM

Thursday

What You Missed On Wall Street On Thursday

+26

Aug 6, 4:15 PM

Midday Fly By: SanDisk, Western Digital slide despite Q4 beats

+25

Aug 6, 11:58 AM

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

+13

Aug 6, 9:48 AM

Charles River price target raised by $36 at Baird, here's why

Aug 6, 9:19 AM

Charles River price target raised by $40 at Deutsche Bank

Aug 6, 9:08 AM

Charles River price target raised by $67 at RBC Capital

Aug 6, 6:44 AM

Wednesday

JPMorgan upgrades Charles River to Overweight following strong Q2

Aug 5, 8:15 PM

JPMorgan gets more bullish on Charles River, upgrades shares

Aug 5, 5:59 PM

Charles River price target raised by $80 at Barclays

Aug 5, 3:17 PM

Charles River price target raised by $40 at Evercore ISI, here's why

Aug 5, 2:53 PM

Early notable gainers among liquid option names on August 5th

Aug 5, 9:55 AM

Morning Movers: Shopify surges following second quarter results

+13

Aug 5, 8:59 AM

Charles River raises FY26 EPS view to $11.15-$11.45 from $10.80-$11.30

Aug 5, 7:20 AM

Charles River reports Q2 EPS $3.02, consensus $2.73

Aug 5, 7:19 AM

Over a week ago

Early notable gainers among liquid option names on July 28th

Jul 28, 9:55 AM

Charles River just downgraded at CLSA, here's why

Jul 20, 5:06 AM

Charles River announces collaboration with Arovella Therapeutics

Jul 13, 8:04 AM

Charles River price target raised by $38 at Mizuho, here's why

Jul 13, 7:43 AM

Charles River price target raised by $40 at Morgan Stanley, here's why

Jul 9, 6:57 AM

Citi adds 'upside 90-day catalyst watch' on Charles River

Jul 8, 6:48 AM

Blair adds American Express, Oracle to Conviction List in monthly update

+39

Jul 1, 6:56 AM

Early notable gainers among liquid option names on June 24th

Jun 24, 9:55 AM

Charles River to collaborate with AI/ML drug discovery platform Lilly TuneLab

Jun 18, 8:12 AM

Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls

+23

Jun 17, 9:47 AM

Comprehensive Service Offering: Charles River provides an integrated, end-to-end portfolio of discovery, preclinical, clinical, and manufacturing support services, acting as a single partner throughout the drug development lifecycle.

Deep Regulatory Expertise: CRL operates with extensive knowledge and strict adherence to global regulatory standards (e.g., FDA, EMA), ensuring high-quality, compliant research and reducing regulatory risk for clients.

Specialized Scientific Talent: The company employs a vast global workforce of highly skilled scientists, veterinarians, and technical specialists, offering deep scientific expertise across diverse therapeutic areas and research methodologies.

Client R&D Spending Volatility: CRL's revenue depends on the research and development budgets of its biopharma clients. Economic downturns or shifts in client priorities could reduce demand for CRL's essential services.

Regulatory Scrutiny and Compliance Costs: Operating under stringent regulations (e.g., FDA, EMA, USDA) for laboratory practices, data integrity, and animal welfare exposes CRL to significant compliance costs and the risk of penalties or operational disruption from non-adherence.

Intense Competition and Pricing Pressure: The contract research organization market is highly competitive, featuring large global players and specialized firms. This environment can lead to pricing pressure, impacting CRL's profit margins and ability to maintain market share.

Charts